Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice

Neuroscience

Volumn 220, Issue , 2012, Pages 256-266

  Marques, S C F ^a,b   Lemos, R ^c   Ferreiro, E ^a   Martins, M ^d,e   de Mendonca A ^e   Santana, I ^a,c   Outeiro, T F ^b,g   Pereira, C M F ^a,f  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^e UNIVERSITY OF LISBON   (Portugal)

^f UNIVERSITY OF COIMBRA   (Portugal)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

3xTg AD mice; Alzheimer's disease; Chromatin remodeling; Histone acetylation; Mild Cognitive Impairment; Peripheral blood mononuclear cells

Indexed keywords

BETA SECRETASE 1; HISTONE H3; MESSENGER RNA;

ADORA2A GENE; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACE1 GENE; CHROMATIN CONDENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC REGULATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MALE; MILD COGNITIVE IMPAIRMENT; MOUSE; NCSTN GENE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; SIRT1 GENE;

AGED; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIRTUIN 1; TRANSCRIPTOME;

EID: 84864770859     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.06.029     Document Type: Article

References (54)

1. Albani D., Polito L., Batelli S., De Mauro S., Fracasso C., Martelli G., Colombo L., Manzoni C., Salmona M., Caccia S., Negro A., Forloni G. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha- synuclein or amyloid-beta (1-42) peptide. J Neurochem 2009, 110:1445-1456.
2. Albasanz J.L., Perez S., Barrachina M., Ferrer I., Martin M. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. Brain Pathol 2008, 18:211-219.
3. Alzheimer's A., Thies W., Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011, 7:208-244.
4. Anderson A.N., Roncaroli F., Hodges A., Deprez M., Turkheimer F.E. Chromosomal profiles of gene expression in Huntington's disease. Brain 2008, 131:381-388.
5. APA (2000) The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text revision (DSM-IV-TR). American Psychiatric association.
6. Arendash G.W., Schleif W., Rezai-Zadeh K., Jackson E.K., Zacharia L.C., Cracchiolo J.R., Shippy D., Tan J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 2006, 142:941-952.
7. Burga A., Casanueva M.O., Lehner B. Predicting mutation outcome from early stochastic variation in genetic interaction partners. Nature 2011, 480:250-253.
8. Cairns B.R. The logic of chromatin architecture and remodelling at promoters. Nature 2009, 461:193-198.
9. Canas P.M., Porciuncula L.O., Cunha G.M., Silva C.G., Machado N.J., Oliveira J.M., Oliveira C.R., Cunha R.A. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 2009, 29:14741-14751.
10. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., Mucke L., Gan L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005, 280:40364-40374.
11. Chouliaras L., Rutten B.P., Kenis G., Peerbooms O., Visser P.J., Verhey F., van Os J., Steinbusch H.W., van den Hove D.L. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol 2010, 90:498-510.
12. Coulson D.T., Beyer N., Quinn J.G., Brockbank S., Hellemans J., Irvine G.B., Ravid R., Johnston J.A. BACE1 mRNA expression in Alzheimer's disease postmortem brain tissue. J Alzheimers Dis 2010, 22:1111-1122.
13. Dall'Igna O.P., Porciuncula L.O., Souza D.O., Cunha R.A., Lara D.R. Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 2003, 138:1207-1209.
14. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370:737-749.
15. Decourt B., Sabbagh M.N. BACE1 as a potential biomarker for Alzheimer's disease. J Alzheimers Dis 2011, 24(Suppl. 2):53-59.
16. Dempster E.L., Pidsley R., Schalkwyk L.C., Owens S., Georgiades A., Kane F., Kalidindi S., Picchioni M., Kravariti E., Toulopoulou T., Murray R.M., Mill J. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet 2011.
17. Donmez G., Wang D., Cohen D.E., Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010, 142:320-332.
18. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92:564-569.
19. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
20. Fraga M.F., Ballestar E., Paz M.F., Ropero S., Setien F., Ballestar M.L., Heine-Suner D., Cigudosa J.C., Urioste M., Benitez J., Boix-Chornet M., Sanchez-Aguilera A., Ling C., Carlsson E., Poulsen P., Vaag A., Stephan Z., Spector T.D., Wu Y.Z., Plass C., Esteller M. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2005, 102:10604-10609.
21. Fukumoto H., Cheung B.S., Hyman B.T., Irizarry M.C. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002, 59:1381-1389.
22. Giresi P.G., Lieb J.D. Isolation of active regulatory elements from eukaryotic chromatin using FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements). Methods 2009, 48:233-239.
23. Grewal S.I., Jia S. Heterochromatin revisited. Nat Rev Genet 2007, 8:35-46.
24. Hebert S.S., Horre K., Nicolai L., Papadopoulou A.S., Mandemakers W., Silahtaroglu A.N., Kauppinen S., Delacourte A., De Strooper B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A 2008, 105:6415-6420.
25. Jiang C., Pugh B.F. Nucleosome positioning and gene regulation: advances through genomics. Nat Rev Genet 2009, 10:161-172.
26. Julien C., Tremblay C., Emond V., Lebbadi M., Salem N., Bennett D.A., Calon F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 2009, 68:48-58.
27. Jung S.S., Gauthier S., Cashman N.R. Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease. Neurobiol Aging 1999, 20:249-257.
28. Kong L.N., Zuo P.P., Mu L., Liu Y.Y., Yang N. Gene expression profile of amyloid beta protein-injected mouse model for Alzheimer disease. Acta Pharmacol Sin 2005, 26:666-672.
29. Long J.M., Lahiri D.K. MicroRNA-101 downregulates Alzheimer's amyloid-beta precursor protein levels in human cell cultures and is differentially expressed. Biochem Biophys Res Commun 2011, 404:889-895.
30. Marques S.C., Oliveira C.R., Pereira C.M., Outeiro T.F. Epigenetics in neurodegeneration: a new layer of complexity. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:348-355.
31. Mastroeni D., Grover A., Delvaux E., Whiteside C., Coleman P.D., Rogers J. Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging 2011, 32:1161-1180.
32. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
33. Murphy M.P., Das P., Nyborg A.C., Rochette M.J., Dodson M.W., Loosbrock N.M., Souder T.M., McLendon C., Merit S.L., Piper S.C., Jansen K.R., Golde T.E. Overexpression of nicastrin increases Abeta production. FASEB J 2003, 17:1138-1140.
34. Nguyen C.T., Gonzales F.A., Jones P.A. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res 2001, 29:4598-4606.
35. Noriega L.G., Feige J.N., Canto C., Yamamoto H., Yu J., Herman M.A., Mataki C., Kahn B.B., Auwerx J. CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability. EMBO Rep 2011, 12:1069-1076.
36. Nunez-Iglesias J., Liu C.C., Morgan T.E., Finch C.E., Zhou X.J. Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. PLoS One 2010, 5:e8898.
37. Papassotiropoulos A., Fountoulakis M., Dunckley T., Stephan D.A., Reiman E.M. Genetics, transcriptomics, and proteomics of Alzheimer's disease. J Clin Psychiatry 2006, 67:652-670.
38. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
39. Portet F., Ousset P.J., Visser P.J., Frisoni G.B., Nobili F., Scheltens P., Vellas B., Touchon J. Mild cognitive impairment (MCI) in medical practice. a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry 2006, 77:714-718. Disease MCIWGotECoAs.
40. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
41. Rouaux C., Jokic N., Mbebi C., Boutillier S., Loeffler J.P., Boutillier A.L. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 2003, 22:6537-6549.
42. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
43. Schonrock N., Humphreys D.T., Preiss T., Gotz J. Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-beta. J Mol Neurosci 2012, 46:324-335.
44. Selvi R.B., Kundu T.K. Reversible acetylation of chromatin: implication in regulation of gene expression, disease and therapeutics. Biotechnol J 2009, 4:375-390.
45. Smith G.E., Pankratz V.S., Negash S., Machulda M.M., Petersen R.C., Boeve B.F., Knopman D.S., Lucas J.A., Ferman T.J., Graff-Radford N., Ivnik R.J. A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms?. Neurology 2007, 69:133-139.
46. Stozicka Z., Zilka N., Novak M. Risk and protective factors for sporadic Alzheimer's disease. Acta Virol 2007, 51:205-222.
47. Strum J.C., Johnson J.H., Ward J., Xie H., Feild J., Hester A., Alford A., Waters K.M. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1. Mol Endocrinol 2009, 23:1876-1884.
48. Urdinguio R.G., Sanchez-Mut J.V., Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009, 8:1056-1072.
49. Whalley L.J., Dick F.D., McNeill G. A life-course approach to the aetiology of late-onset dementias. Lancet Neurol 2006, 5:87-96.
50. Wu Z.L., Ciallella J.R., Flood D.G., O'Kane T.M., Bozyczko-Coyne D., Savage M.J. Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol Aging 2006, 27:377-386.
51. Yamakuchi M., Ferlito M., Lowenstein C.J. MiR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 2008, 105:13421-13426.
52. Yang L.B., Lindholm K., Yan R., Citron M., Xia W., Yang X.L., Beach T., Sue L., Wong P., Price D., Li R., Shen Y. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003, 9:3-4.
53. Zhao G., Liu Z., Ilagan M.X., Kopan R. Gamma-secretase composed of PS1/Pen2/Aph1a can cleave notch and amyloid precursor protein in the absence of nicastrin. J Neurosci 2010, 30:1648-1656.
54. Zhong L., Dong-hai Q., Hong-ying L., Qing-feng L. Analysis of the nicastrin promoter rs10752637 polymorphism and its association with Alzheimer's disease. Eur J Neurosci 2009, 30:1831-1836.